DocGo (DCGO) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue reached $164.9M, up 31% year-over-year, with net income rising to $5.9M and adjusted EBITDA of $17.2M, reflecting strong operational execution and new business development momentum.
Mobile Health Services revenue rose 46% to $116.7M, while Transportation Services increased 6% to $48.2M, driven by government contracts and new partnerships.
Cash and equivalents at June 30, 2024, were $85.8M, up from $58.9M at Q1 end, with cash flow from operations exceeding $35M in Q2.
The company is expanding partnerships across payers, providers, hospital systems, and municipal health, with several new contracts and a two-year UK contract extension.
Migrant-related project wind-downs in New York are freeing resources for new growth opportunities and expected to improve margins.
Financial highlights
Q2 2024 total revenue: $164.9M (+31% YoY); mobile health revenue: $116.7M (+46% YoY); transportation revenue: $48.2M (+6% YoY).
Net income for Q2 2024 was $5.9M, up from $1.3M in Q2 2023; basic and diluted EPS were $0.06.
Adjusted EBITDA margin improved to 10.4% from 7.3% YoY; GAAP gross margin was 31.3% (up from 30.3%), and adjusted gross margin was 33.9% (up from 33.4%).
SG&A as a percentage of revenue dropped to 27.7% from 32.1% YoY, reflecting cost control and a targeted reduction in force.
Cash and equivalents at June 30, 2024, were $85.8M, up from $58.9M at Q1 end.
Outlook and guidance
2024 revenue guidance reaffirmed at $600–$650M, with adjusted EBITDA of $65–$75M.
Cash flow from operations guidance raised to $80–$90M for 2024, up from $70–$80M.
Base business revenue expected to be $400M in 2025, excluding potential migrant-related revenues; 2025 base business projected to grow over 30% with adjusted EBITDA margin above 10%.
Medical transportation projected to grow 15–20% annually; mobile health segment expected to see even larger growth.
Mobile Health Services revenue expected to decline in H2 2024 as migrant-related projects wind down, despite new project launches.
Latest events from DocGo
- 2026 guidance raised on core growth and SteadyMD gains, with H2 profitability targeted.DCGO
Q4 202516 Mar 2026 - Scaling tech-enabled mobile healthcare with record volumes and strong growth outlook.DCGO
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - All proposals passed, with strong financials and strategic growth initiatives outlined.DCGO
AGM 20243 Feb 2026 - Strong Q2 growth, cash gains, and a shift to sustainable health programs drive 2024 optimism.DCGO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Transitioning from migrant contracts, the company targets $400M in core business growth for 2025.DCGO
Stifel 2024 Cross Sector Insight Conference1 Feb 2026 - Core mobile health business is set for strong growth as migrant revenue phases out.DCGO
15th Annual Midwest IDEAS Investor Conference23 Jan 2026 - Rapidly growing mobile healthcare leverages tech and in-home care to cut costs and hospitalizations.DCGO
Morgan Stanley 22nd Annual Global Healthcare Conference21 Jan 2026 - Rapidly scaling in-home care business, targeting strong growth and improved margins.DCGO
2024 Cantor Global Healthcare Conference20 Jan 2026 - Q3 revenue fell 26%, but net income and cash flow surged, with guidance and contracts strengthened.DCGO
Q3 202415 Jan 2026